Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease

Recruiting now · Phase 4 · Has a placebo group

Conditions studied: End Stage Renal Disease on Dialysis

In brief

The main purpose of the study is to determine if empagliflozin can reduce peritoneal glucose absorption in patients with end stage renal diease (ESRD) on peritoneal dialysis. This is a randomized, placebo controlled, acute crossover study of empagliflozin in an anticipated 30 chronic PD patients, with an 8 week "pre post" open label extension in all 30 patients where they will receive empagliflozin daily.

Key facts

Study ID

NCT05671991

Run by

Yale University

People needed

30

Starts

2023-03-01

Expected to finish

2026-12-31

Last updated by the study team

2026-05-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients actively undergoing PD with a reliably functioning PD catheter
• Stable peritoneal dialysis prescription
• PD vintage > 3 months
• Age >18 years of age

You may not qualify if…

• History of type 1 diabetes, diabetic ketoacidosis, "brittle" diabetes or frequent hypoglycemia or severe hypoglycemic episodes requiring emergent intervention (ER visit or EMS response, glucagon administration or forced oral carbs) in the last 6 months
• Use of an SGLT2 inhibitor within the prior 30 days
• 1 or more episodes of peritonitis in the previous 6 months or active infection of the peritoneal dialysis catheter
• Anemia with hemoglobin <8g/dL
• Inability to give written informed consent or follow study protocol
• Contraindication to receiving loop diuretics

Where it is running

• Yale University — New Haven, Connecticut, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.